Bharat Biotech's COVID-19 vaccine, Covaxin is effective against the Delta Plus variant of coronavirus, an ICMR study said
Bharat Biotech's COVID-19 vaccine, Covaxin is effective against the Delta Plus variant of coronavirus, an ICMR study said, reported news agency ANI. Covaxin is India's first indigenous vaccine against COVID-19 developed by Bharat Biotech in collaboration with ICMR.
The Delta Plus COVID variant is a mutated form of the highly transmissible Delta variant that was first detected in India last year in October. Union Science and Technology Minister Jitendra Singh last week said in Parliament that 70 cases of the highly transmissible Delta Plus were found by INSACOG, a group of 28 laboratories that conduct genome sequencing.
Hyderabad-based Bharat Biotech in July had said Covaxin is 77.8 percent effective against symptomatic COVID infection while it gives 65.2 protection against the Delta COVID variant. Covaxin has received emergency use authorisations in 15 nations, including Brazil, India, the Philippines, and EUAs are in process in 50 other nations worldwide, the vaccine maker said.
Bharat Biotech's Covaxin got emergency use authorisation by the Indian drug regulator earlier this year, on January 3, even when the data on the vaccine's efficacy was not published.
The interim report on Covaxin released in March showed that it was 81 percent effective against coronavirus. The second interim analysis released in April showed that the vaccine was 100 percent effective against severe COVID-19 disease.
India on July 9 also submitted documents required for Emergency Use Listing (EUL) to the World Health Organization (WHO) for Covaxin, and the health agency has started, Minister of State for Health Bharati Pravin Pawar told Rajya Sabha
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
 "Covaxin effective against Delta Plus variant of coronavirus: ICMR study")
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
)
){kind=small}
){kind=small}
)
)
)
)
)
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}